Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GV1001 with gemcitabine + capecitabine in advanced pancreatic cancer
2006-000461-10Phase 3Completed
- Sponsor
- Royal Liverpool University Hospital
- Start
- Jul 2006
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tertomotide, gemcitabine, capecitabine and sargramostim in pancreatic adenocarcinoma (PDAC) and pancreatic cancer (PC) (3 arms), sponsored by Royal Liverpool University Hospital. Primary endpoint: Overall survival. Started Jul 2006; status: completed.
02
Drugs
tertomotidegemcitabinecapecitabinesargramostim
03
Conditions
pancreatic adenocarcinoma (PDAC)pancreatic cancer (PC)
Beyond the preview
Go deeper on 2006-000461-10.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-000461-10.